The TRAILBLAZER Open-Label Extension (OLE) is a continuation study that allows participants who completed the main TRAILBLAZER-ALZ 2 Phase 3 trial to continue receiving donanemab treatment. This extension provides valuable long-term safety data and allows participants who benefited from treatment to maintain access to the investigational therapy.
Donanemab is a monoclonal antibody developed by Eli Lilly that targets a specific form of aggregated amyloid-beta plaque known as pyroglutamate-modified Aβ (pE3-Aβ). This plaque form is considered particularly toxic and represents a key target in Alzheimer's disease immunotherapy.
- Phase: Extension Study
- Status: Ongoing
- Sponsor: Eli Lilly and Company
- NCT Number: NCT05520231
- Duration: Up to 24 months additional treatment
- Patient Population: Participants who completed TRAILBLAZER-ALZ 2
- Enrollment: Approximately 600 participants expected
¶ Background and Rationale
¶ Amyloid Hypothesis and Immunotherapy
The amyloid cascade hypothesis posits that accumulation of amyloid-beta peptides in the brain is the primary initiating event in Alzheimer's disease pathogenesis. Amyloid plaques composed of Aβ40 and Aβ42 peptides accumulate decades before clinical symptoms appear, triggering a cascade of downstream pathologies including tau tangles, neuroinflammation, and neuronal loss.
Donanemab represents a next-generation anti-amyloid antibody with enhanced specificity for aggregated forms of Aβ. Unlike earlier generation antibodies that targeted monomeric or soluble Aβ, donanemab preferentially binds to pyroglutamate-modified Aβ (pE3-Aβ), a highly aggregated and neurotoxic form found prominently in amyloid plaques[@simoni2024].
The parent trial TRAILBLAZER-ALZ 2 (NCT04437511) was a Phase 3 study evaluating donanemab in patients with early-stage Alzheimer's disease (MCI due to AD or mild dementia due to AD). Key findings included:
- Primary Endpoint: Significant slowing of clinical decline on iADRS (Integrated Alzheimer's Disease Rating Scale) at 76 weeks
- Amyloid Reduction: Mean reduction of 61% in amyloid plaque burden as measured by PET
- Tau Reduction: Delayed progression of tau pathology in treatment responders
- Subgroup Effects: Benefits observed across ApoE4 carrier status and baseline disease severity
Donanemab targets aggregated amyloid through multiple mechanisms:
- Plaque Targeting: Binds with high affinity to N-terminal truncated and modified forms of amyloid-beta (pE3-Aβ)
- Plaque Removal: Promotes clearance through antibody-mediated phagocytosis (opsonization)
- Plaque Reduction: Demonstrated significant reduction in amyloid plaques (61% mean reduction)
- Microglial Activation: Engages microglia via Fc receptor-mediated pathways to enhance plaque clearance
Donanemab's specificity for pE3-Aβ distinguishes it from earlier anti-amyloid antibodies:
- Pyroglutamate Aβ: Forms at position 3 of Aβ through cyclization of glutamate
- Aggregation Propensity: pE3-Aβ exhibits enhanced aggregation compared to unmodified Aβ
- Plaque Enrichment: pE3-Aβ is enriched in dense-core plaques
- Toxicity: Associated with synaptic dysfunction and neuronal loss
The OLE follows an open-label design:
- Eligibility: Participants completing the double-blind treatment period in TRAILBLAZER-ALZ 2
- Treatment: Donanemab 350mg IV every 4 weeks for up to 24 months
- Assessments: Continued monitoring of safety and efficacy
- Imaging: Periodic amyloid PET imaging to confirm sustained plaque clearance
- Screening: Confirmation of eligibility from parent study
- Monthly Visits: IV infusions and safety monitoring
- Quarterly: Clinical assessments (MMSE, CDR, iADRS)
- 6-Month Intervals: Amyloid PET, MRI for ARIA monitoring
- Long-term safety and tolerability of donanemab (up to 24 months continuous treatment)
- Treatment response durability in participants with sustained amyloid clearance
- Continued assessment of clinical progression using validated cognitive scales
- Amyloid plaque reaccumulation rates after sustained clearance
- Biomarker studies including plasma tau and neurofilament light chain (NfL)
- Health economic outcomes and quality of life measures
- Subgroup analyses by baseline characteristics
- Biomarker correlates of treatment response
- Mechanisms of amyloid rebound upon treatment discontinuation
Preliminary results from the OLE indicate:
- Consistent with Parent Trial: Safety profile remains consistent with TRAILBLAZER-ALZ 2
- ARIA-E (Amyloid-Related Imaging Edema): Incidence remains the main safety concern; most cases mild to moderate and manageable
- ARIA-H (Hemorrhage): Microhemorrhages observed in some participants; monitoring continues
- Infusion Reactions: Generally mild and manageable with standard protocols
- Sustained Benefit: Participants maintaining clinical benefits with continued treatment
- Plaque Clearance: Sustained amyloid clearance in majority of participants
- Treatment Effects: Continued slowing of clinical decline in treatment responders
- Biomarkers: Plasma NfL trajectories suggest neuroprotection in responders
- Lower discontinuation rates compared to parent study due to established tolerability
- Participants who completed parent study demonstrate improved adherence
The TRAILBLAZER OLE provides critical information for several outstanding questions in AD treatment:
- Safety data beyond 18 months of continuous treatment
- Cumulative exposure data in larger patient populations
- Understanding of late-onset adverse events
- Optimal treatment duration questions remain under investigation
- Biomarker-guided treatment decisions based on amyloid clearance thresholds
- Re-initiation of treatment upon amyloid rebound
- Evidence for sustained disease-modifying effects with prolonged treatment
- Correlation between amyloid clearance and clinical outcomes over extended periods
- Long-term impact on disease progression trajectories
- Clinical outcomes in broader patient populations
- Real-world adherence and tolerability
- Healthcare resource utilization data
Donanemab (Kisunla™) received FDA approval in July 2024 for treatment of early-stage Alzheimer's disease. The OLE continues to generate post-marketing data to support:
- Label updates with long-term safety and efficacy data
- Treatment guidelines for clinical practice
- Reimbursement discussions with payers